Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2007) 14 P184

ECE2007 Poster Presentations (1) (659 abstracts)

Factors affecting height velocity (HV) during GnRH analog therapy in girls with central precocious puberty (CPP)

Dimitrios Thomas 1 , Elpis Vlachopapadopoulou 1 , Feneli Karachaliou 1 , Eirini Vourliotaki 1 , Philippos Kaldrimides 2 & Stefanos Michalakos 1

109 views


1Dept. of Growth and Development, Children’s Hosp. “P. & A. Kyriakou”, Athens, Greece; 2Dept. of Endocrinology and Metabolism, “Metaxa” Memorial Anticancer Research Hospital, Piraeus, Greece.


Aim: To assess factors affecting HV during triptorelin suppression treatment for CPP.

Materials and methods: Forty-six girls with CPP, with mean age at diagnosis 8.4 yrs who presented with signs and symptoms of puberty before the age of 8 years and were treated with triptorelin for at least 2 years, were studied. All girls were categorized into three groups according to the difference between bone age (BA) and chronological age (ΔBA-CA): group I with ΔBA-CA<11.99 months, group II with ΔBA-CA between 12 and 23.99 months and group III with ΔBA-CA>24 months. Furthermore, girls were categorized in two groups: girls with BA before treatment initiation ≤10 years and girls with BA >10 years. Four groups were formed according to Tanner breast staging: group A,B,C,D with breasts TII, TII-III, TIII and TIII-IV respectively.

Results: A statistically significant difference in mean HV during the 2nd year of treatment was observed between group I (5.99±2.21), group II (3.87±1.46) and group III (3.09±1.47) (P=0.012, AN.O.VA). Mean HV during the 2nd year of treatment was statistically higher in girls with BA before treatment ≤10 years (5.78±1.75) compared to girls with BA before treatment >10 years (3.17±1.27) (P=0.0001, t-test). A statistically significant difference in mean HV during the 1st year of treatment was observed between group A (6.32±0.96), group B (5.56±0.97), group C (4.96±1.07), and group D (4.26±1.66) (P=0.05, Kruskal-Wallis AN.O.VA). HV during the second year of treatment could be statistically predicted using bone age (P=0.002) and weight (P=0.036) before treatment initiation as independent factors in multivariate linear regression model, according to the following equation: HV2nd year=15,026−0,702X(BA)-0,0892X(W).

Conclusions: Bone age, Tanner breast stage and weight seem to be important factors affecting HV during triptorelin therapy for CPP.

Article tools

My recent searches

No recent searches.